DEXTENZAの薬剤に関する洞察と市場予測：2032年

DEXTENZAは、まぶたの自然な開口部である点鼻から眼管に挿入されるコルチコステロイドの眼内挿入剤であり、防腐剤を使用せずにデキサメタゾンを最長30日間眼表面に送達するように設計されています。治療後、DEXTENZAは再吸収され、除去の必要なく鼻涙系から排出されます。

当レポートでは、米国におけるDEXTENZA市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性疼痛におけるDEXTENZAの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 DEXTENZA市場評価

• 急性疼痛におけるDEXTENZAの市場展望
• 米国の分析
  • 米国における急性疼痛に対するDEXTENZAの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

• 参考文献
• レポート調査手法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: DEXTENZA, Clinical Trial Description, 2023
• Table 2: DEXTENZA, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: DEXTENZA Market Size in the US, in USD million (2019-2032)

List of Figures

• Figure 1: DEXTENZA Market Size in the United States, USD million (2019-2032)

"DEXTENZA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about DEXTENZA for acute pain in the United States. A detailed picture of the DEXTENZA for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the DEXTENZA for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DEXTENZA market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.

Drug Summary:

DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eyelid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Following treatment, DEXTENZA resorbs and exits the nasolacrimal system without needing removal.

Dosage and administration

• DEXTENZA is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus. A single DEXTENZA insert releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion.
• DEXTENZA is resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert if necessary. DEXTENZA is intended for single use only.

Mechanism of action

Dexamethasone, a corticosteroid, suppresses inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DEXTENZA description, mechanism of action, dosage and administration, research and development activities in acute pain.
• Elaborated details on DEXTENZA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DEXTENZA research and development activities in acute pain across the United States.
• The report also covers the patents information with expiry timeline around DEXTENZA.
• The report contains forecasted sales of DEXTENZA for acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute pain.
• The report also features the SWOT analysis with analyst views for DEXTENZA in acute pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DEXTENZA Analytical Perspective by DelveInsight

In-depth DEXTENZA Market Assessment

This report provides a detailed market assessment of DEXTENZA for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

DEXTENZA Clinical Assessment

The report provides the clinical trials information of DEXTENZA for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DEXTENZA dominance.
• Other emerging products for acute pain are expected to give tough market competition to DEXTENZA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DEXTENZA in acute pain.
• Our in-depth analysis of the forecasted sales data of DEXTENZA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DEXTENZA in acute pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of DEXTENZA?
• What is the clinical trial status of the study related to DEXTENZA in acute pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DEXTENZA development?
• What are the key designations that have been granted to DEXTENZA for acute pain?
• What is the forecasted market scenario of DEXTENZA for acute pain?
• What are the forecasted sales of DEXTENZA in the United States?
• What are the other emerging products available and how are these giving competition to DEXTENZA for acute pain?
• Which are the late-stage emerging therapies under development for the treatment of acute pain?

Table of Contents

1. Report Introduction

2. DEXTENZA Overview in Acute pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DEXTENZA Market Assessment

• 5.1. Market Outlook of DEXTENZA in Acute pain
• 5.2. The United States Analysis
  • 5.2.1. Market Size of DEXTENZA in the United States for Acute pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options